CU Anschutz News reports that FDA-approved intranasal esketamine therapy is provided for major depressive disorder when traditional treatments have not worked.
Intranasal esketamine report
CU Anschutz News reports that FDA-approved intranasal esketamine therapy is provided to patients with major depressive disorder who have not responded to traditional treatments. The source presents the therapy in the context of treatment-resistant depression. Its report describes the treatment as an option for patients whose prior traditional treatment response has not been sufficient.
What the source says
According to CU Anschutz News, the therapy is intranasal esketamine and is FDA-approved. The source identifies major depressive disorder as the diagnosis in its description and says the patients concerned have not responded to traditional treatments. CU Anschutz News does not provide, in the supplied extract, details about assessment, referral, treatment schedules, follow-up, or other practical arrangements.
Director’s view
CU Anschutz News identifies Andrew Novick as program director. The source says Novick emphasizes that innovative treatments are vital for reducing suicide risk and improving outcomes for patients with treatment-resistant depression. CU Anschutz News attributes that assessment to Novick. The supplied extract does not include numerical results or a comparison of outcomes between esketamine and other treatments.
Limits of the report
The CU Anschutz News extract is focused on the therapy’s stated role for people with major depressive disorder who have not responded to traditional treatments. It does not state that every patient with depression is eligible. In the supplied material, CU Anschutz News does not give information about costs, insurance coverage, availability, wait times, or how many patients receive treatment.
What this means for Colorado patients
For people looking for treatment locally, the directory lists 114 published clinics in Colorado. CU Anschutz News identifies intranasal esketamine as a reported option for major depressive disorder when traditional treatments have not produced a response. Readers can use the directory to find local treatment listings while recognizing the treatment terms described in the source.
This is general information, not medical advice.
More Colorado reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.